Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)

NCT05700721 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Brain Metastases

Interventions

DRUG: Niraparib
DRUG: Dostarlimab

Sponsor

M.D. Anderson Cancer Center